Corresponding author

1. Sleep-related adverse events of smoking cessation drugs: A network meta-analysis of randomized controlled trials. Psychiatry Res. 335, 115874.

2. Association between coenzyme Q 10-related genetic polymorphisms and statin-associated myotoxicity in Korean stroke patients. Front Pharmacol. 15, 1358567.

3. Transporter Genes and statin-induced Hepatotoxicity. Cardiovasc Drugs Ther. Published online.

4. A risk-scoring system to predict dupilumab-associated ocular surface disease in patients with atopic dermatitis. Front Pharmacol. 15, 1425550.

5. Effects of CYP3A5 Genetic Polymorphisms on the Weight-adjusted through Concentration of Sirolimus in Renal Transplant Recipients: A Systematic Review and Meta-analysis. Curr Pharm Des. 30, 3108-3115.

Corresponding author

1. Evaluation of low-molecular-weight heparin for treatment of portal vein thrombosis in liver cirrhosis patients. Medicina-Lithuania. 59, 2922.

2. Risk factors for palbociclib-induced early developing neutropenia in patients with hormone receptor-positive metastatic breast cancer. Cancers. 15, 2810.

3. Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States. Front Pharmacol. 14, 1205624.

4. Correlation between PPARG Pro12Ala polymorphism and therapeutic responses to thiazolidinediones in patients with type 2 diabetes: a meta-analysis. Pharmaceutics, 15, 1778.

5. Interactive associations between PPARγ and PPARGC1A and bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis. Pharmaceuticals, 16, 1035.

6. Effects of CYP3A4*22 polymorphism on trough concentration of tacrolimus in kidney transplantation: a systematic review and meta-analysis. Front Pharmacol. 14, 121083. 

7. Association between genetic polymorphisms in fibrinogen genes and bleeding risk in patients treated with direct oral anticoagulants. Ann Acad Med Singap. 52, 340-347. 

8. Novel gene polymorphisms for stable warfarin dose in a Korean population: Genome-wide association study. Biomedicines. 11, 2308. 

9. ABCG2 gene polymorphisms may affect bleeding risk in patients on apixaban and rivaroxaban. Drug Des Devel Ther. 17, 2513-2522.

10. Association between SLCO1B1 genetic  polymorphisms and bleeding risk in patients treated with edoxaban. Sci Rep. 13, 15967. 

11. Machine learning-based prediction of risk factors for abnormal glycemic control in diabetic cancer patients receiving nutrition support: a case–control study. Hormones (Athens). 22, 637-645.

12. Construction of a risk scoring system using clinical factors and RYR2 polymorphisms for bleeding complications in patients on direct oral anticoagulants. Front Pharmacol. 14, 1290785.

Coauthor

1. Prediction of medication-related osteonecrosis of the jaws using machine learning methods from estrogen receptor 1 polymorphisms and clinical information. Front Med., 10, 1140620. 

Corresponding author

1.        Association between SLCO1B1 polymorphism and methotrexate-induced hepatotoxicity: a systematic review and meta-analysis. Anticancer Drugs. 33, 75-79.

2.        Genetics factors of renin-angiotensin system associated with major bleeding for patients treated with direct oral anticoagulants. Pharmaceutics. 14, 231.

3.        Association of P450 oxidoreductase gene polymorphism with tacrolimus pharmacokinetics in renal transplant recipients: a systematic review and meta-analysis. Pharmaceutics. 14, 

261.

4.        Antihypertensive drug use and psoriasis: A systematic review, meta- and network meta-analysis. Br J Clin Pharmacol. 88, 933-941.

5.        Association between ABCG2 421C>A (rs2231142) polymorphism and rosuvastatin pharmacokinetics: a systematic review and meta-analysis. Pharmaceutics. 14, 501.

6.        Risk scoring system for vancomycin-associated acute kidney injury. Front Pharmacol. 13, 815188.

7.        A risk scoring system utilizing machine learning methods for hepatotoxicity prediction one year after the initiation of tyrosine kinase inhibitors. Front Oncol. 12, 790343.

8.        Effect of ITPA polymorphism on adverse drug reactions of 6-mercaptopurine in pediatric patients with acute lymphoblastic leukemia: a systematic review and meta-analysis. Pharmaceuticals. 15, 416.

9.        Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: a meta-analysis. Travel Med Infect Dis. 48, 102333

10.      Proton pump inhibitor use and hearing loss in patients with type 2 diabetes: evidence from a hospital-based case-control study and a population-based cohort study. Br J Clin Pharmacol. 88, 2738-2746

11.      Global research trends of gender-related artificial intelligence in medicine between 2001-2020: A bibliometric study. Front Med. 9, 868040.

12.      Influence of GNAS and RGS gene polymorphisms on ritodrine-induced adverse events in preterm labor women. Pharmaceutics. 14, 1220.

13.      Association of SLC47A1 gene variant with responses to metformin monotherapy in drug-naïve patients with type 2 diabetes: A systematic review and meta-analysis. J Clin Endocrinol Metab. 107, 2684-2690.

14.    Risk factors for vancomycin-associated acute kidney injury: a systematic review and meta-analysis. Br J Clin Pharmacol. 88, 3977-3989.

15.    Association between genetic polymorphisms and bleeding in patients on direct oral anticoagulants. Pharmaceutics. 14, 1889.

Corresponding author

1.        Analysis of risk factors for hepatotoxicity induced by immune checkpoint inhibitors. J Immunother, 44, 16-21.

2.        Short-term exposure to air pollution and hospital admission for pneumonia: a systematic review and meta-analysis. Environ Health, 20, 6.

3.        Association between attention deficit hyperactivity disorder and aggression subscales in adolescents. Brain Behav, 11, e02030.

4.        ABCA1 69C>T polymorphism and the risk of type 2 diabetes mellitus: a systematic review and meta-analysis. Front Endocinol. 12, 639524.

5.        Angiotensin-converting enzyme inhibitor use and psoriasis: A systematic review and meta-analysis. Sci Rep. 11, 10037.

6.        Machine learning approaches to predict hepatotoxicity risk in patients receiving nilotinib. Molecules. 26, 3300.

7.        Association between CYP2C9 genotype and hypoglycemia among type 2 diabetic patients receiving sulfonylurea treatment: a meta-analysis. Clin Ther, 43, 836-843.

8.        Machine learning approaches for predicting bisphosphonate-related osteonecrosis in women with osteoporosis using VEGFA gene polymorphisms. J Pers Med. 11, 541.

9.        Influence of CYP2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite E-3174: A systematic review and meta-analysis. J Pers Med. 11, 617.

10.      Risk scoring system of mortality and prediction model of hospital stay for critically ill patients receiving parenteral nutrition. Healthcare. 9, 853.

11.      Association between CYP3A5 polymorphism and statin-induced adverse events: A systemic review and meta-analysis. J Pers Med. 11, 677.

12.     Gene polymorphisms of the renin–angiotensin system and bleeding complications of warfarin: genetic-based machine learning models. Pharmaceuticals. 14, 824.

13.      Effects of SLCO1B1 and SLCO1B3 genetic polymorphisms on valsartan pharmacokinetics in healthy Korean volunteers. J Pers Med. 11, 862.

14.      Smartphone addiction and anxiety in adolescents-A cross-sectional study. Am J Health Behav. 45, 895-901.

15.      Association between ABCA1 gene polymorphisms and plasma lipid concentration: a systematic review and meta-analysis. J Pers Med. 11, 883.

16.      Association between ADCY9 gene polymorphisms and ritodrine treatment outcomes in patients with preterm labor. Pharmaceutics, 13, 1653.

17.      Association between statin use and sensorineural hearing loss in type 2 diabetic patients: a hospital-based study. Pharmaceuticals, 14, 1076.

18.      TGF-β1 polymorphism increases the risk of bleeding complications in patients on oral anticoagulant after cardiac valve replacement. Heart Vessels. 36, 1885-1891.

19.      Effects of ephedrine-containing products on weight loss and lipid profiles: a systematic review and meta-analysis of randomized controlled trials. Pharmaceuticals. 14, 1198.

Corresponding author

1.        Effects of pharmacist interventions on reducing prescribing errors of investigational drugs in oncology clinical trials. J Oncol Pharm Pract. 26, 29-35.

2.        Factors influencing imatinib-induced hepatotoxicity. Cancer Res Treat. 52, 181-188.

3.        Health behaviors associated with aggression in Korean adolescents: data from 2 cross-sectional studies. Am J Health Behav. 44, 271-282.

4.        Population pharmacokinetics of sulindac and genetic polymorphisms of FMO3 and AOX1 in women with preterm labor. Pharm Res. 37, 44.

5.        Influence of GRK5 gene polymorphisms on ritodrine efficacy and adverse drug events in preterm labor treatment. Sci Rep. 10, 1351.

6.        Association between glutathione-S-transferase gene polymorphisms and responses to TKI treatment in patients with chronic myeloid leukemia: a meta-analysis. Target Oncol. 15, 47-

           54.

7.        The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systemic review and meta-analysis. Sci Rep. 10, 3658.

8.        Effects of citrulline supplementation on body weight in patients with hepatobiliary pancreatic surgery. Nutr Clin Pract. 35, 323-330.

9.        Vancomycin pharmacokinetics in critically ill neonates receiving extracorporeal membrane oxygenation. Eur J Hosp Pharm. 27, e25-e29.

10.    Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan. Eur J Clin Pharmacol. 76, 723-729.

11.    Genotype-guided warfarin dosing may benefit patients with mechanical aortic valve replacements: randomized controlled study. Sci Rep. 10, 6988.

12.    Association between preoperative use of antithrombotic medications and intraoperative transfusion in older patients undergoing cancer surgery. Asian J Surg. 43, 585-592.

13.    Low cyclosporine concentrations in children and time to acute graft versus host disease. BMC Pediatr. 20, 206.

14.    Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects. Mol Genet Genom Med. 8, e1201.

15.    Influence of CYP2C9 and CYP2A6 gene polymorphisms on plasma concentrations of valproic acid: a meta analysis. Eur J Clin Pharmacol. 76, 1053-1058.

16.    Effects of KCNMB2 gene polymorphisms on ritodrine therapy in women with preterm labor. Pharmacogenet Genomics. 30, 124-130.

17.    Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study. Eur J Clin Pharmacol. 76, 1183-1191.

18.    Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: A systemic review and meta-analysis. 

         Br J Clin Pharmacol. 86, 1489-1498.

19.    Association of pre-operative medication use with unplanned 30-day hospital readmission after surgery in oncology patients receiving comprehensive geriatric assessment. 

   Am J of Surg. 219, 963-968.

20.    The impact of drug interactions on adverse effects of oral oxycodone in male geriatric patients. J Clin Pharm Ther. 45, 976-982.

21.    Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis. Sci Rep. 10, 17390.

22.    Clinical manifestations and perinatal outcomes of pregnant women with COVID-19: a systematic review and meta-analysis. Sci Rep. 10, 18126.

Coauthor

1.        Suyeon Kang, Jeong Yee, Jae Youn Kim, Hye Won Han, Sang Oh Kang, Kyung Eun Lee, Hye Sun Gwak, Factors associated with voriconazole concentration in pediatric patients. 

      Ther Drug Monit. 42, 866-871 (2020)

Corresponding author

1.        Effects of cyclic parenteral nutrition on parenteral nutrition-associated cholestasis in newborns. Asia Pac J Clin Nutr. 28, 42-48.

2.        Association between anxiety and aggression in adolescents: a cross-sectional study. BMC Pediatr. 19, 115.

3.        Effects of polymorphisms in Myc-related genes on bleeding complications in patients with stable warfarin responses. Cardiovasc Ther, 2019, 1-8 (ID 1813747).

4.        Genetic variations in the transcription factors GATA4 and GATA6 and bleeding complications in patients receiving warfarin therapy. Drug Des Devel Ther. 13, 1717-1727.

5.        Association between VEGFA gene polymorphisms and bleeding complications in patients maintaining therapeutic international normalized ratio. Pharmacogenomics, 20, 659-667.

6.        Comparisons of doxycycline solution with talc slurry for chemical pleurodesis and risk factors for recurrence in South Korean patients with spontaneous pneumothorax. Eur J 

  Hosp Pharm. 26, 275-279.

7.        Risk factors for neutropenia following prophylactic pegfilgrastim. Asia Pac J Clin Oncol. 15, 231-237.

8.        Association between HNF4A mutations and bleeding complications in patients with stable INR. Pharmacogenet Genomics. 29, 200-206.

9.        Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study. Br J Clin Pharmacol. 

           85, 1719-1727.

10.    Effects of PDE4 gene polymorphisms on efficacy and adverse drug events of ritodrine therapy in preterm labor patients: a prospective observational study. Eur J Clin Pharmacol. 75, 

         1379-1386.

11.    APOB gene polymorphisms may affect the risk of minor or minimal bleeding complications in patients on warfarin maintaining therapeutic INR. Eur J Hum Genet. 27, 1542-1549.

12.    Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity, Breast Cancer Res Treat. 178, 239-244.

13.    Effects of proton pump inhibitor use on risk of Clostridium difficile infection: a hospital cohort study. J Gastroenterol. 54, 1052-1060.

Coauthor

1.        Cristiano Fava et al. Effects of CYP4F2, VKORC1 and CYP2C9 in influencing coumarin dose. A single-patient data meta-analysis in more than 15,000 individuals. Clin Pharmacol 

           Ther. 105, 1477-1491 (2019).

Corresponding author

1.        Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and stable warfarin doses. Gene. 641, 68-73.

2.        Pre-operative medication use and its association with postoperative length of hospital stay in surgical oncology patients receiving comprehensive geriatric assessment. 

           Geriatr Gerontol Int. 18, 12-19.

3.        Effects of concomitant medication use on gefitinib-induced hepatotoxicity. J Clin Pharmacol. 58, 263-268.

4.        Smartphone addiction risk and daytime sleepiness in Korean adolescents. J Paediatr Child Health. 54, 800-806.

5.        Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity. Anticancer Drugs. 29, 471-476.

6.        Association between MKRN3 and LIN28B polymorphisms and precocious puberty. BMC Genet. 19, 47.

7.        Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study. BMC Cancer. 18, 988.

8.        Association of pre-operative medication use with post-surgery mortality and morbidity in oncology patients receiving comprehensive geriatric assessment. Aging Clin Exp Res. 30, 

           1177-1185.

9.        Risk factors of opioid-induced adverse reactions in elderly male outpatients of Korea Veterans Hospital. BMC Geriatr. 18, 293.

10.    Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients. Med Oncol. 35, 154.

Corresponding author

1.        Evaluation of the predictors of readmission in Korean patients with heart failure. J Clin Pharm Ther. 42, 51-57.

2.        Influence of NR3C1 and VDR polymorphisms on stable warfarin dose in patients with mechanical cardiac valves. Int J Cardiol. 236, 393-397.

3.        Outcomes with perioperative fat emulsions containing omega-3 fatty acids: A meta-analysis of randomized controlled trials. Am J Health Syst Pharm. 74, 904-918.

4.        Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients. Eur J Clin Pharmacol. 73, 837-842.

5.        New anticoagulants for the prevention and treatment of venous thromboembolism. Biomol Ther. 25, 461-470.

6.        Factors for time to trastuzumab-induced cardiotoxicity in breast cancer patients. Med Oncol. 34, 199.

7.        Association between ß2-adrenergic receptor gene polymorphisms and adverse events of ritodrine in the treatment of preterm labor: a prospective observational study. BMC Genet. 

           18, 96.

Coauthor

1.        Effects of adrenal androgen levels on bone age advancement in prepubertal children: using of the Ewha Birth and Growth Cohort Study. J Korean Med Sci. 32, 968-973.

2.        Elevated metabolites of steroidogenesis and amino acid metabolism in preadolescent female children with high urinary bisphenol A levels: A high-resolution metabolomics study. 

Toxicol Sci. 160, 371-385.

Corresponding author

1.        Association of inflammatory gene polymorphisms with mechanical heart valve reoperation. SpringerPlus. 5, 937.

2.        Association of pre-operative medication use with post-operative delirium in surgical oncology patients receiving comprehensive geriatric assessment. BMC Geriatr. 16, 134.

Corresponding author

1.        Role of the nuclear pregnane X receptor in drug metabolism and the clinical response. Receptors & Clinical Investigation. 2, e996.

2.        Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses. Pharmacogenet Genomics. 25, 38-40.

3.        Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves. Pharmacogenomics J. 15, 33-37.

4.        Effects of single nucleotide polymorphisms in c-Myc on stable warfarin doses in patients with cardiac valve replacements. Pharmacogenomics. 16, 1101-1108.

5.        Effects of pregnane X receptor genetic polymorphisms on stable warfarin doses. J Cardiovasc Pharm Ther. 20, 532-538.

6.        Influence of UDP-glucuronosyltransferase polymorphisms on stable warfarin doses in patients with mechanical cardiac valves. Cardiovas Ther. 33, 324-328.

7.        Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. Eur J Clin Pharmacol. 71, 1229-1236.

8.        INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation. Int J Clin Pharm. 37, 1038-1046.

9.        Application of mono-directional Janus patch to oromucosal delivery system. Adv Healthc Mater. 4, 2229-2236.

Coauthor

1.        Comparison of usage and effectiveness between methoxy polyethylene glycol epoetin beta and darbepoetin alfa with hemodialysis patients. J Pharm Pharmacol. 3, 182-190.

2.        The preventive effect of breast-feeding for longer than 6 months on early pubertal development among children aged 7-9 years in Korea. Public Health Nutr. 18, 3300-3307.

3.        Relationship of serum 25-Hydroxyvitamin D (25[OH]D) levels and components of metabolic syndrome in prepubertal children. Nutrition. 31, 1324-1327.

Corresponding author

1.        Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates. Am J Health Syst Pharm. 71, 122-127.

2.        Effects of single nucleotide polymorphisms of FMO3 and FMO6 genes on pharmacokinetic characteristics of sulindac sulfide in preterm labor. Drug Metab Dispos.42, 40-43.

3.        Development of clinical pharmacy services for intensive care units in Korea. SpringerPlus. 3, 34.

4.        Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves. J Clin Pharm Ther. 39, 314-318.

5.        Effects of inflammatory cytokine gene polymorphisms on warfarin maintenance doses in Korean patients with mechanical cardiac valves. Arch Pharm Res.,37, 752-759.

6.        Effects of β2-adrenergic receptor gene polymorphisms on ritodrine therapy in pregnant women with preterm labor: prospective follow-up study. Int J Mol Sci. 15, 12885-12894.

7.        Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems. Eur J Drug Metab Pharmacokinet. 39, 237-242.

Coauthor

1.        Factors associated with smoking among high school students in Korea. Int J Contemp Pediatr. 1, 65-73. 

2.        Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials. Perit Dial Int.34, 724-731.

Corresponding author

1.        Adequate intensity of warfarin therapy for Korean patients with mechanical cardiac valves. J. Heart Valve Dis. 22, 102-109.

2.        Pharmacokinetic characteristics of capsaicin-loaded nanoemulsions fabricated with alginate and chitosan. J Agr Food Chem. 61, 2096-2102.

3.        Formulation and in vitro/in vivo evaluation of levodopa transdermal delivery systems. Int J Pharm. 456, 432-436.

4.        Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats. J Pharm Pharmacol. 65, 1195-1203.

5.        Comparisons of budesonide and dexamethasone for local treatment of oral chronic graft-versus-host disease. Am J Health-Syst Pharm. 70, 1383-1391.

Coauthor

1.        Longitudinal changes in offspring body weight, fat mass and sex hormone levels according to maternal bisphenol A exposure during gestation and lactation. Mol Cell Toxicol. 9, 

285-293.

2.        Association of vitamin D concentrations with adiposity indices among preadolescent children in Korea. J Pediatr Endocrinol Metabol. 26, 849-854.

3.        A cross-sectional study of factors related to gastrointestinal drug use in Korean adolescents. Arch Pharm Res. 36, 1238-1243.

4.        Mendelian randomization analysis of the effect of maternal homocysteine during pregnancy, as represents by maternal MTHFR C677T genotype, on birth weight. J Epidemiol. 23, 

371-375.

5.        Effect of urinary bisphenol A on androgenic hormones and insulin resistance in preadolescent girls: a pilot study from the Ewha Birth & Growth Cohort. Int J Environ Res Publ 

Health. 10, 5737-5749.

Corresponding author

1.        Quantitative determination of aceclofenac and its three major metabolites in rat plasma by HPLC-MS/MS. J Sep Sci. 35, 2219-2222.

2.        Effects of CYP4F2 polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. Ther Drug Monit. 34, 275-282.

3.        Effects of bile salts on gastrointestinal absorption of pravastatin. J Pharm Sci. 101, 2281-2287.

Corresponding author

1.        Effects of vehicles on the percutaneous absorption of donepezil hydrochloride across the excised hairless mouse skin. Drug Dev Ind Pharm. 37, 1125-1130.

2.        Design and evaluation of levodopa methyl ester intranasal delivery systems. J Parkinson Dis. 1, 101-107.

3.        Effects of bile salts on the lovastatin pharmacokinetics following oral administration to rats. Drug Deliv. 18, 79-83.

4.        Effects of amines on percutaneous absorption of alendronate. Drug Dev Ind Pharm. 37, 491-497.

Corresponding author

1.        Pharmacokinetic characteristics of formulated alendronate transdermal delivery systems in rats and humans. Drug Deliv.,17, 249-254 (2010).

2.        Interaction between warfarin and Korean red ginseng in patients with cardiac valve replacement. Int J Cardiol. 145, 275-276 (2010).

3.        Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. Eur J Pharm Sci. 38, 525-532 (2009).

4.        Formulation and evaluation of ubidecarenone transdermal delivery systems. Drug Dev Ind Pharm. 35, 1029-1034 (2009).

5.        Internet overuse and excessive daytime sleepiness in adolescents. Psychiat Clin Neuros. 63, 455-462 (2009).

6.        Comparison of bioavailability of two ubidecarenone products in healthy Korean volunteers. Int J Clin Pharmacol Ther. 47, 207-214 (2009).

7.        The effects of terpenes on the permeation of lidocaine and ofloxacin from moisture-activated patches. Drug Deliv. 16, 75-81 (2009).

8.        The effects of fatty acids in propylene glycol on the percutaneous absorption of alendronate across the excised hairless mouse skin. Int J Pharm. 357, 126-131 (2008).

9.        Pharmacokinetics of formulated tenoxicam transdermal delivery systems. J Pharm Pharmacol. 60, 135-138 (2008).

10.      Formulation and evaluation of ondansetron nasal delivery system. Int J Pharm. 349, 101-107 (2008).

11.      Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers. Drug Dev Ind Pharm. 33, 824-829 (2007).

12.      Formulation and evaluation of ketorolac transdermal systems. Drug Del. 14, 69-74 (2007).

Coauthor

1.        Paraoxonase 1 gene and glutathione S-transferase μ 1 gene interaction with preterm delivery in Korean women. Am J Obs Gyn. 203, 569.e1-e7 (2010).

2.        Stability of n-acetylcysteine in peritoneal dialysis solution. Perit Dial Int. 30, 105-108 (2010).

3.        Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cell. Drug Deliv. 16, 261-267 (2009).

4.        Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother. 64, 388-391 (2009).

First/Corresponding author

1.        Enhanced bioavailability of piroxicam via salt formation with ethanolamines. Int J Pharm. 297, 156-161 (2005).

2.        Effects of non-steroidal anti-inflammatory drugs on the pharmacokinetics and elimination of acyclovir in rats. J Pharm Pharmacol. 57, 393-398 (2005).

3.        Stability of roxatidine in parenteral nutrient solutions containing different amino acid injections. Am J Health-Syst Pharm. 62, 289-291 (2005).

4.        Determination of amosulalol in human plasma using solid-phase extraction combined with high performance liquid chromatography and ultraviolet detection. J Chromatogr B. 818, 

  109-113 (2005).

5.        The effect of vehicles and pressure sensitive adhesives on the percutaneous absorption of quercetin through the hairless mouse skin. Arch Pharm Res. 27, 763-768 (2004).

6.        Transdermal delivery of ketorolac tromethamine: effects of vehicles and penetration enhancers. Drug Dev Ind Pharm. 30, 557-564 (2004).

7.        Transdermal delivery of ondansetron hydrochloride: effects of vehicles and penetration enhancers. Drug Dev Ind Pharm. 30, 187-194 (2004).

8.        Analgesic effects of intra-nasal enkephalins. J Pharm Pharmacol. 55, 1207-1212 (2003).

9.        In vitro percutaneous absorption of ondansetron hydrochloride from pressure-sensitive adhesive matrices through hairless mouse skin. Arch Pharm Res. 26, 644-648 (2003).

10.      Effect of vehicles and enhancers on the in vitro permeation of melatonin through hairless mouse skin. Arch Pharm Res. 25, 392-396 (2002).

11.      Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. Int J Pharm. 236, 57-64 (2002).

12.      In vitro percutaneous absorption of tenoxicam from     pressure-sensitive adhesive matrices through hairless mouse skin. Arch Pharm Res. 24, 578-583 (2001).

13.      Effect of vehicles and enhancers on the in vitro skin permeation of aspalatone and its enzymatic degradation across rat skins. Arch Pharm Res. 24, 572-577 (2001).

1.       Mijin Lee, Ji Min Han, Young Ock Kim, Jeong Yee, Hye Sun Gwak, Kyung Hee Choi, Differences in pharmacogenomic information reflected in approved drug label of Korea and the United States. Yakhak Hoiji. 65, 174-182 (2021). (Corresponding).

2.       Mijin Lee, Sukyung Kim, Jeong Yee, Hye Sun Gwak, Kyung Hee Choi, Analysis of pharmacogenetic information in Korea drug labels, Kor J Clin Pharm. 31, 21-26 (2021) (Corresponding)

3.       Ha Young Yoon, Young Ah Cho, Jeong Yee, Hye Sun Gwak, Ji Min Han, Clinical and laboratory features of pediatric patients with COVID-19: Systematic review and meta-analysis, Kor J Clin Pharm. 30, 270-278 (2020) (Corresponding)

4.       Ji Min Han, Hye Sun Gwak, Reviews on the hepatotoxicity of tyrosine kinase inhibitors. Kor J Clin Pharm. 29, 223-230 (2019). (Corresponding)

5.       Jin Young Moon, Yeonhong Lee, Young Ju Kim, Hye Sun Gwak. Analysis of prescribing errors of investigational drugs in oncology clinical trials. Kor J Health-Syst Pharm. 36, 366-373 (2019). (Corresponding).

6.       Joo Hee Kim, Jeong Yee, Gwan Yung Lee, Kyung Eun Lee, Hye Sun Gwak. Comparison of approval process for non-prescription drugs in different countries. Kor J Clin Pharm. 28, 263-272 (2018). (Corresponding).

7.       So Yeon Cho, Jeong Yee, Wonku Kang, Jae Yeon Kim, Sook Hee An, Hye Sun Gwak. Population pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation in pediatric patients. Kor J Clin Pharm. 28, 24-29 (2018). (Corresponding).

8.       Nayoung Han, Ju-Yeun Lee, Hye Sun Gwak, Byung Koo Lee, Young Sook Lee, Sukhyang Lee, Chul-Soon Yong, Joo Hee Kim, Jung Mi Oh, Selection of tasks for assessment of pharmacy clinical performance in Korean pharmacist licensure examination: results of an expert survey. Kor J Clin Pharm. 27, 119-126 (2017).

9.       Joo Hee Kim, Ju-Yeun Lee, Young Sook Lee, Chul-Soon Yong, Nayoung Han, Hye Sun Gwak, Jungmi Oh, Byung Koo Lee, Sukhyang Lee. Attitudes to proposed assessment of pharmacy skills in Korean pharmacist licensure examination. J Educ Eval Health Prof. 14, 6 (2017).

10.   Bo Kyeong Kang, Sook Hee An, Jae Youn Kim, Hye Sun Gwak. Comparisons of efficacy between dapagliflozin and sitagliptin in combination with metformin in type 2 diabetes mellitus patients. Kor J Clin Pharm. 27, 99-104 (2017). (Corresponding)

11.   Joo Hee Kim, Hye Sun Gwak. Novel oral anticoagulants for the treatment of venous thromboembolism in cancer patients. Kor J Clin Pharm. 26, 269-282 (2016). (Corresponding)

12.   Yoon Kyung Kim, Sook Hee An, Jae Yeon Kim, Jee Eun Chung, Hye Sun Gwak. Comparisons of bleeding risks between rivaroxaban and dalteparin for treatment of venous thromboembolism in cancer patients. Kor J Clin Pharm. 26, 195-200 (2016). (Corresponding)

13.   Hye Kyung Jin, Jee Eun Chung, Kyung Suk Choi, Sandy Rhie, Hye Sun Gwak, Byung Koo Lee, Joon Suk Hong, Young Ju Kim, Mi Hye Park. Medication utilization during pregnancy and development of educational materials for safe use of medication. J Korean Soc Mater Child Health. 20, 12-24 (2016).

14.   Ji Hye Bark, Sunny Park, Jae Youn Kim, Joo Hee Kim, Hye Sun Gwak. Comparative effectiveness between dipeptidylpeptidase-4 inhibitors and sulfonylureas in combination with metformin in type 2 diabetes mellitus patients. Kor J Clin Pharm. 25, 42-47 (2015). (Corresponding)

15.   Mi Rang Kim, Min Sun Kim, Youn Ju Lee, Seoung Lan Kim, Yang Sook Na, Hye Sun Gwak, Jae Yeon Kim. Analysis of the loss amounts of hygroscopic drug in powder form in dispensing, storage and process improvement to decrease loss. Kor J Health-Syst Pharm. 31, 1092-1098 (2014).

16.   Heejung Lee, Mikyong Shim, Jungeun Ha, Hyunah Kim, Hongseop Moon, Hyesun Gwak, Kyungeob Choi. Analysis of factors related to the students' satisfaction on 6-year pharmacy program and strategic planning. Kor J Clin Pharm. 24, 288-295 (2014).

17.   Jung Yeon Moon, Sae Won Kim, Kyung Eun Lee, Hye Sun Gwak. Correlation between aggression and health behaviors of Korean high school students, Kor J Clin Pharm. 24, 144-153 (2014). (Corresponding)

18.   Ji Hye Park, Byung Koo Lee, Jae Yeon Kim, Hye Sun Gwak. Comparisons of adherence, efficacy and price between sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in type 2 diabetes mellitus patients. Kor J Clin Pharm. 24, 193-198 (2014). (Corresponding)

19.   Hye-min Lim, Sa-mi Yang, Yun-hee Park, Hye-won Han, Hye-sun Gwak, Jae-yeon Kim. Efficacy of fluconazole prophylaxis for invasive fungal infection in extremely low birth weight infants. Kor J Health-Syst Pharm. 31, 919-927 (2014).

20.   Se-hui Jo, Sa-mi Yang, Jae-youn Kim, Hye-sun Gwak, Young-cheon Song. Association between sodium intake and intraventricular hemorrheage in preterm infants. Kor J Health-Syst Pharm. 30, 220-230 (2013).

21.   Hyun Jung Lee, Ji Young Choi, Jae Yeon Kim, Young Cheon Song, Hye Sun Gwak. The risk of hypotension following the co-prescription of macrolide antibiotics and calcium channel blockers. Kor J Health-Syst Pharm. 30, 130-140 (2013).

22.   Ho-seok Jang, Min-kyoung Kang, Young-seol Heo, Hee-se Kim, Hye-sun Gwak, Yeong-cheon Song. Frequency and related factors analysis of cetuximab infusion reactions. Kor J Health-Syst Pharm. 30, 12-19 (2013).

23.   Hee Joo Park, Hyen-Oh La, Hye Sun Gwak. Effects of diuretics on warfarin responses in patients with atrial fibrillation. Kor J Clin Pharm. 23, 151-157 (2013). (Corresponding)

24.   Eun Jung Kim, Kyung Eun Lee, Hye Sun Gwak. Analysis of ethnic differences in Physician’s Desk Reference. Kor J Clin Pharm. 23, 123-128 (2013). (Corresponding)

25.   Hee Young Yoon, Byung Koo Lee, Hye Sun Gwak. Stability of triamcinolone added in three oral liquid syrups. Kor J Clin Pharm. 22, 176-180 (2012). (Corresponding)

26.   Sae-Jin Jung, Sang-Soo Lee, Kyung Eun Lee, Byung Koo Lee, Hye Sun Gwak. Perception and attitude towards antidepressants in Koreans. Kor J Clin Pharm. 22, 65-72 (2012). (Corresponding)

27.   Young-Jong Lee, Ok-Sun Park, Yun-Hee Park, Jae-Yeon Kim, Young-Chun Song, Hye-Sun Gwak. Analysis of risk factors affecting Cytomegalovirus infection according to medication uses after kidney transplantation. Kor J Health-Syst. Pharm. 28, 153-160 (2011).

28.   Bo-Ram Sin, Heo-Jung Lee, Yun-Hee Park, Jae-Youn Kim, Hye-Sun Gwak, Young-Cheon Song. Risk of thromboembolism with the angiogenesis inhibitor bevacizumab in metastatic colo-rectal cancer patients. Kor J Health-Syst Pharm. 28, 279-287 (2011).

29.   Jung Sun Heo, Kyung Hee Kim, In Kyung Yoon, Hyun Ju Kim, You Jin Kim, Jong Min Choi, Hwa Jeong Lee, Hye Sun Gwak. Analysis of gender differences in Physician’s Desk Reference. Kor J Clin Pharm. 21, 22-29 (2011). (Corresponding)

30.   Hyun Ju Kim, Jong Min Choi, You Jin Kim, Song Wha Chae, Jung Hyun Park, Ji Hyun Oh, Kyung Hee Kim, Jung Sun Heo, Hye Sun Gwak, Hwa Jeong Lee. Review of gender differences in medicine and primary factors resulting in gender differences. Kor J Clin Pharm. 20, 128-137 (2010). (Corresponding)

31.   Hyun Ae Choi, Ji Young Choi, Youn Hee Park, Jae Yeon Kim, Yeong Cheon Song, Hye Sun Gwak. Analysis of drug interaction between simvastatin and cyclosporine. Kor J Health-Syst Pharm. 27, 313-322 (2010).

32.   Jee-hye Jeong, Seong-gil Ryu, Jae-youn Kim, Hye-Sun Gwak, Young-cheon Song. Changes in blood concentrations of cyclosporine after combination with azoles in bone marrow transplant recipients. Kor J Health-Syst Pharm. 27, 110-118 (2010).

33.   So Jung Yoon, Young Chun Song, Jae Yeon Kim, Byung Koo Lee, Kyung Hee Kim, Hye Sun Gwak. Optimal glycemic control to reduce mortality in surgical intensive care unit. Kor J Clin Pharm. 20, 107-113 (2010). (Corresponding)

34.   Sin Ae Chung, Hye Sun Gwak, In Koo Chun, Seang Yeol Oh. Levodopa transport through skin using iontophoresis: the role of electroosmosis and electrorepulsion. J Kor Pharm Sci. 38, 31-38 (2008).

35.   Sin Ae Chung, Hye Sun Gwak, In Koo Chun, Seang Yeol Oh. Iontophoretic delivery of levodopa: permeation enhancement by oleic acid microemulsion and ethanol. J Kor Pharm Sci 38, 373-380 (2008).

36.   Na Rae Bae, Hye Jin Choi, Byung Koo Lee, Hye Sun Gwak. Factors associated with effectiveness of and rash occurrence by epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer. Kor J Clin Pharm. 18, 75-83 (2008). (Corresponding)

37.   Ji Won Yoon, Byung Koo Lee, Young Chun Song, Jae Yeon Lim, Hye Young Shin, Yeon Hong Lee, Hye Sun Gwak. The comparisons of effectiveness and compliance among alendronate pharmaceutical products. Kor J Clin Pharm. 18, 114-119 (2008). (Corresponding)

38.   Eun Young Kim, Won Ku Kang, Hye Sun Gwak. Comparison of analytical methods of tacrolimus in plasma and population pharmacokinetics in liver transplant recipients. Kor J Clin Pharm. 18, 60-67 (2008). (Corresponding)

39.   Hye Sun Gwak, In Koo Chun. Bioequivalence evaluation of two atenolol tablet preparations in Korean healthy male volunteers. J Appl Pharmacol. 15, 187-191 (2007).

40.   Hyo Sook Song, Byung Chul Chang, Hye Sun Gwak. Analysis of warfarin-induced complications in patients with mechanical heart valve replacement in emergency center. Kor J Clin Pharm. 17, 70-75 (2007). (Corresponding)

41.   Hye Sun Gwak, Na Young Lee, In Koo Chun. Simplified HPLC method for the determination of mirtazapine in human plasma and its application to single-dose pharmacokinetics. J Appl Pharmacol. 14, 40-44 (2006).

42.   Hye-Kyung Kim, Hye-Sun Gwak. Stability of cefditoren in three liquid oral preparations. Kor J Clin Pharm. 16, 28-33 (2006). (Corresponding)

43.   Ah Mee Kim, Hye Sun Gwak, In Koo Chun. Formulation and evaluation of moisture-activated acyclovir patches. J Kor Pharm Sci. 36, 393-399 (2006). (Corresponding)

44.   Hee Eun Kim, Hye Sun Gwak. Current status and expectation of orphan drugs in Korea – in point of supplying medicines for the rare diseases. Kor J Clin Pharm. 16, 107-112 (2006). (Corresponding)

45.   Hye Sun Gwak, In Koo Chun. Simplified HPLC method for the determination of prazosin in human plasma and its application to single-dose pharmacokinetics. J Appl Pharmacol. 13, 90-94 (2005).

46.   Jung Ok Jang, Hye Sun Gwak, Hwa Jeong Lee. Encapsulation of plasmid DNA in pegylated liposome. J Kor Pharm Sci. 35, 337-341 (2005).

47.   Ju-Yeon Jung, Sun-Young Jung, Hye-Sun Gwak. Prevalence and determinants of influenza vaccination in Koreans. Kor J Clin Pharm. 15, 89-93 (2005). (Corresponding)

48.   Yoon-Hee Kim, Young-Hye Chung, Hwa-Jeong Lee, Hye-Sun Gwak. Post-marketing surveillance study of the safety and efficacy of mesoglycan prescribed in primary and secondary care of patients with vascular disease. Kor J Clin Pharm. 15, 94-99 (2005). (Corresponding)

49.   Hyesun Gwak, Yeonhwa Song, Inkoo Chun. Preparation and release properties of oromucosal moisture-activated patches containing lidocaine or ofloxacin. J Kor Pharm Sci. 35, 417-422 (2005).

50.   Hye-Sun Gwak, Kyung-Ho Park, Jun-Shik Choi, Gin-A Song, Min-Kyung Sung, Jung-Ok Jang, Hwa-Jeong Lee. Determination of ethambutol in human plasma by a validated HPLC method and its application to single-dose pharmacokinetics. J Kor Pharm Sci. 35, 123-127 (2005).

51.   Hae-Young Park, Hye-Sun Gwak, In-Koo Chun. Determination of bumetanide in human plasma by a validated HPLC method and its application to single-dose pharmacokinetics. J Kor Pharm Sci. 35, 51-55 (2005).

52.   Youngah Cho, Junghyun Oh, Hongseop Moon, In Choi, Junshik Choi, Hyesun Gwak. Stability of aminophylline, ceftriaxone sodium and ampicillin/sulbactam in total parenteral nutrient solution. Kor J Clin Pharm. 14, 96-99 (2004). (Corresponding)

53.   Hye Sun Gwak, Hye Won Kim, In Koo Chun. Solubility and physicochemical stability of quercetin in various vehicles. J Kor Pharm Sci. 34, 29-34 (2004).

54.   Hye Sun Gwak, Ik Sang Oh, In Koo Chun. Solubility and physicochemical stability of ondansetron hydrochloride in various vehicles. J Kor Pharm Sci. 33, 45-49 (2003).

55.   Hye Sun Gwak, Sung Ha Kang, In Koo Chun. Bioequivalence of Sinil atenolol tablets to tenormin tablets (atenolol 50mg). J Kor Pharm Sci. 33, 51-56 (2003).

56.   Hye Sun Gwak, Seung Ung Kim, In Koo Chun. Formulation and evaluation of melatonin plasters. J Kor Pharm Sci. 32, 107-112 (2002).

57.   Yun Jin Lee, Hye Sun Gwak, In Koo Chun. Preformulation study of aloesin in buffered aqueous solutions. Yakhak Hoeji. 46, 168-173 (2002).

58.   Hye Sun Gwak, In Sook Park, In Koo Chun. Enhanced permeation of leucine enkephalin and [D-Ala2]-leucine enkephalinamide across nasal, rectal and vaginal mucosae of rabbit. J Appl Pharmacol. 10, 104-113 (2002).

59.   Eun Jung Jung, Hye Sun Gwak, Jun Shik Choi, Jin Hwan Lee, Xiuguo Li. Pharmacokinetics of paclitaxel in rabbits with renal failure induced by folic acid. Kor J Clin Pharm. 12, 91-95 (2002). 

60.   In Koo Chun, Hye Sun Gwak. Permeation and enzymatic degradation of aspalatone in gastrointestinal tract of rabbit, J Kor Pharm Sci. 31, 27-35 (2001).

61.   Hye Sun Gwak, In Koo Chun. Preformulation study of aspalatone, a new antithrombotic agent, J Appl Pharmacol. 8, 332-337 (2000).

Hye Sun Gwak, In Koo Chun. Effect of cyclodextrins on the solubility and stability of aspalatone in aqueous solutions. J Kor Pharm Sci. 30, 267-271 (2000).